Osteoarthritis and Bone Disorders News

Amniotic suspension allograft may be an effective nonoperative treatment of symptomatic knee osteoarthritis, according to recently published results.

Rheumatology patients treated with interleukin inhibitors have an increased risk for serious infections, opportunistic infections and cancer, according to data published in JAMA Open Network.

Individuals prescribed high-dose statin therapy to manage cardiovascular risk are more likely to receive a diagnosis of osteoporosis compared with those prescribed a low-dose statin or no therapy, according to findings from a database analysis published in Annals of Rheumatic Diseases.

Physical therapy and lifestyle counseling are underused as prescriptions for pain medications, including narcotics, continue to increase for patients with knee osteoarthritis, according to findings published in Arthritis Care & Research.

Social support appears to be a prognostic factor for some outcomes, including long-term beneficial impacts on certain WOMAC and Oxford Knee scores, following total hip or knee replacement, according to findings published in The Lancet Rheumatology.

The American Association of Clinical Endocrinologists joined the International Osteoporosis Foundation in support of World Osteoporosis Day on Sunday, calling on health care providers to make osteoporosis and fracture prevention a priority in daily clinical practice, according to a press release.

After a reexamination procedure, a European Medicines Agency committee announced a positive opinion recommending marketing authorization for romosozumab for the treatment of severe osteoporosis in postmenopausal women at high risk for fracture with no history of myocardial infarction or stroke, according to a press release from Amgen and UCB.

SAN DIEGO — Taking a ‘holiday’ from many osteoporosis drugs can frequently negate gains in bone density, according to a presentation at the 2019 Congress of Clinical Rheumatology West.

Patients with knee osteoarthritis who received a high sprifermin dose of 100 g administered every 6 or 12 months, demonstrated significantly improved total femorotibial joint cartilage thickness after 2 years, although it remains unclear whether these findings are clinically important, according to phase 2 data published in JAMA.

SAN DIEGO — Understanding which drugs and drug classes contribute to adverse bone effects, including bone loss and fractures, may be extremely useful for rheumatologists and their patients, according to a presentation at the 2019 Congress of Clinical Rheumatology West.